DK2320900T3 - Opioider til anvendelse til behandling af patienter med resistent cancer - Google Patents

Opioider til anvendelse til behandling af patienter med resistent cancer Download PDF

Info

Publication number
DK2320900T3
DK2320900T3 DK09776348.6T DK09776348T DK2320900T3 DK 2320900 T3 DK2320900 T3 DK 2320900T3 DK 09776348 T DK09776348 T DK 09776348T DK 2320900 T3 DK2320900 T3 DK 2320900T3
Authority
DK
Denmark
Prior art keywords
cells
cancer
resistance
apoptosis
methadone
Prior art date
Application number
DK09776348.6T
Other languages
English (en)
Inventor
Erich Miltner
Claudia Friesen
Andreas Alt
Original Assignee
Universität Ulm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Ulm filed Critical Universität Ulm
Application granted granted Critical
Publication of DK2320900T3 publication Critical patent/DK2320900T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (13)

1. Anvendelse af opioider, der kan inhibere proliferation af cancerceller, til fremstilling af et lægemiddel til behandling af patienter med resistent cancer.
2. Anvendelse ifølge krav 1, hvor cancerpatienten har mindst én resistens fra den følgende gruppe: apoptoseresistens, kemoresistens, stråleresistens.
3. Anvendelse ifølge mindst et af de foregående krav, hvor patienten enten har en iboende eller erhvervet resistens.
4. Anvendelse ifølge et af de foregående krav, hvor patienten har en eller flere af de følgende resistenser: i. apoptoseresistens ii. resistens over for flere lægemidler (multiresistens) iii. resistens over for anticancerlægemidler iv. resistens over for cytotoksiske lægemidler v. resistens over for reaktive oxygenarter vi. resistens over for DNA-beskadigende stoffer vii. resistens over for toksiske antistoffer viii. doxorubicin-resistens ix. enkelt- eller krydsresistens, især over for et eller flere af de følgende lægemidler: methotrexat, cytarabin, cisplatin, etoposid, vineristin, paclitaxel, carboplatin, teniposid, dexamethason, prednisolon, cyclophosphamid, diphosphamid, doxorubicin, epirubicin, daunorubicin, mercaptopurin x. resistens over for stråling (f.eks. alfa, beta, gamma eller Auger-elektroner) .
5. Anvendelse ifølge mindst et af de foregående krav, hvor patienterne har en af de følgende cancertyper: leukæmi, hjernecancer, melanom, pancreascancer, brystcancer, blærecancer, colonkarcinom, levercancer, ovariecancer, mammacancer, lungecancer, kronisk leukæmi eller osteosarkom.
6. Anvendelse ifølge mindst et af de foregående krav, hvor patienterne har ikke-solide tumorer fra gruppen bestående af akut lymfoblastisk leukæmi, akut myeloid leukæmi, kronisk myeloid leukæmi, kronisk lymfocytisk leukæmi, forstadier af leukæmier, hårcelleleukæmi, Hodgkins sygdom, non-Hodgkins lymfom og multipel myelom.
7. Anvendelse ifølge mindst et af de foregående krav, hvor opioidet kan inducere den mitokondriske apoptose-pathway i cancercellerne.
8. Anvendelse ifølge krav 7, hvor opioidet kan inducere apoptose ved hjælp af mindst en af de følgende reaktioner: i. spaltning af caspase-3 og PARP i tumorcellen ii. spaltning af caspase-9 og nedregulering af XIAP iii. nedregulering af BclXL
9. Anvendelse ifølge mindst et af de foregående krav, hvor opioidet tilhører metadongruppen.
10. Anvendelse ifølge mindst et af de foregående krav, hvor opioidet er hydrochloridformen af D-/L-metadon.
11. Farmaceutisk præparat omfattende en terapeutisk virksom mængde af et opioid (bestanddel A) og mindst ét yderligere anticancermiddel (bestanddel B) , der er udvalgt fra gruppen bestående af methotrexat, cytarabin, cisplatin, etoposid, vineristin, især doxorubicin eller betastråling eller gammastråling, til anvendelse til behandling af patienter med resistent cancer.
12. Anvendelse ifølge mindst ét af kravene 1 til 8, hvor opioidet er udvalgt fra gruppen bestående af fentanyl, buprenorfin og morfin.
13. Opioider, der kan inhibere proliferation af cancerceller, til anvendelse til behandling af patienter med resistent cancer.
DK09776348.6T 2008-07-31 2009-01-29 Opioider til anvendelse til behandling af patienter med resistent cancer DK2320900T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08013741.7A EP2149372B1 (en) 2008-07-31 2008-07-31 Use of opioids of the methadone group for the treatment of resistant cancer patients
PCT/EP2009/000584 WO2010012319A1 (en) 2008-07-31 2009-01-29 Use of opioids or opioid mimetics for the treatment of resistant cancer patients

Publications (1)

Publication Number Publication Date
DK2320900T3 true DK2320900T3 (da) 2016-10-24

Family

ID=40011012

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08013741.7T DK2149372T3 (da) 2008-07-31 2008-07-31 Anvendelse af opioider af metadongruppen til behandling af patienter med resistent cancer
DK09776348.6T DK2320900T3 (da) 2008-07-31 2009-01-29 Opioider til anvendelse til behandling af patienter med resistent cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08013741.7T DK2149372T3 (da) 2008-07-31 2008-07-31 Anvendelse af opioider af metadongruppen til behandling af patienter med resistent cancer

Country Status (13)

Country Link
US (1) US8901175B2 (da)
EP (2) EP2149372B1 (da)
JP (1) JP5804945B2 (da)
CN (1) CN102159212B (da)
BR (1) BRPI0916555B1 (da)
CA (1) CA2732497C (da)
DK (2) DK2149372T3 (da)
ES (2) ES2482168T3 (da)
HU (1) HUE031337T2 (da)
PL (2) PL2149372T3 (da)
PT (2) PT2149372E (da)
RU (1) RU2520636C2 (da)
WO (1) WO2010012319A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
PL2716291T3 (pl) * 2012-10-08 2020-06-15 Universität Ulm Połączenie opioidów i leków przeciwnowotworowych do leczenia nowotworów
AU2018351502A1 (en) * 2017-10-20 2020-03-26 Purdue Pharma L.P. Pharmaceutical dosage forms
WO2019197015A1 (en) 2018-04-09 2019-10-17 Peter Truog Composition comprising 4-phenylbutyric acid derivatives & opioids
CN110090303B (zh) * 2019-05-07 2022-09-16 浙江大学 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途
WO2020239948A1 (en) 2019-05-28 2020-12-03 Isanas Ag A CENTRALLY ACTING µ-OPIOID RECEPTOR AGONIST IN COMBINATION WITH A CURCUMINOID FOR USE IN THE TREATMENT OF A TUMOUR OF THE CENTRAL NERVOUS SYSTEM

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173486A (en) * 1991-08-26 1992-12-22 Bristol-Myers Squibb Company Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents
PL1885187T3 (pl) * 2005-05-13 2014-03-31 Novartis Ag Sposoby leczenia lekoopornego raka

Also Published As

Publication number Publication date
DK2149372T3 (da) 2014-07-07
PT2320900T (pt) 2016-10-13
EP2149372B1 (en) 2014-04-02
PL2320900T3 (pl) 2017-01-31
JP5804945B2 (ja) 2015-11-04
EP2149372A1 (en) 2010-02-03
EP2320900A1 (en) 2011-05-18
US20110270011A1 (en) 2011-11-03
EP2320900B1 (en) 2016-07-06
HUE031337T2 (hu) 2017-07-28
RU2520636C2 (ru) 2014-06-27
PL2149372T3 (pl) 2015-03-31
WO2010012319A1 (en) 2010-02-04
CN102159212A (zh) 2011-08-17
RU2011107280A (ru) 2012-09-10
ES2596363T3 (es) 2017-01-09
JP2011529454A (ja) 2011-12-08
ES2482168T3 (es) 2014-08-01
BRPI0916555A2 (pt) 2015-11-10
CA2732497A1 (en) 2010-02-04
US8901175B2 (en) 2014-12-02
CA2732497C (en) 2017-01-17
BRPI0916555B1 (pt) 2021-06-29
CN102159212B (zh) 2015-09-16
PT2149372E (pt) 2014-07-25

Similar Documents

Publication Publication Date Title
US11052082B2 (en) Combination of opioids and anticancer drugs for cancer treatment
Basu The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy
Berger et al. NF-κB is required for smac mimetic-mediated sensitization of glioblastoma cells for γ-irradiation–induced apoptosis
Afsharimani et al. Morphine and tumor growth and metastasis
Friesen et al. Cell death sensitization of leukemia cells by opioid receptor activation
DK2320900T3 (da) Opioider til anvendelse til behandling af patienter med resistent cancer
US8828451B2 (en) Akt sensitization of cancer cells
Pham et al. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications
EP2968379B1 (en) Etoposide prodrugs for use in targeting cancer stem cells
O'Steen et al. Venetoclax synergizes with radiotherapy for treatment of B-cell lymphomas
Stehle et al. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma
Guo et al. Brusatol modulates diverse cancer hallmarks and signaling pathways as a potential cancer therapeutic
Che et al. Oridonin promotes apoptosis and restrains the viability and migration of bladder cancer by impeding TRPM7 expression via the ERK and AKT signaling pathways
ArulJothi et al. Implications of reactive oxygen species in lung cancer and exploiting it for therapeutic interventions
Ma et al. BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations
Zheng et al. Targeting Cullin-RING E3 ligases for radiosensitization: from NEDDylation inhibition to PROTACs
Chen et al. HMGB1 in the interplay between autophagy and apoptosis in cancer
Chugh Experimental therapies and clinical trials in bone sarcoma
Ghandadi et al. TNF-α exerts higher cytotoxic effect on MCF-7 multidrug resistant derivative, role of Akt activation
RU2792057C2 (ru) Комбинация ингибитора mcl-1 и стандартного лекарственного препарата для лечения гематологических злокачественных новообразований, её применение и содержащие её фармацевтические композиции
Li et al. Matrine induces autophagic cell death by triggering ROS/AMPK/mTOR axis and apoptosis in multiple myeloma
Kunjachan et al. PO-0983: Nanoparticle mediated tumor vascular disruption: A novel strategy in radiation therapy
IT201800002694A1 (it) MOLECOLE CHE INIBISCONO PKB/AKT COMPROMETTENDO LA FOSFORILAZIONE DI Ser941 DI RBL2/p130
Ihnen et al. 515 Therapeutic advantage of chemotherapy drugs in combination with PARP inhibitor PF-01367338 (AG-014699) in human ovarian cancer cells
TW201125868A (en) Method of treating cancer using combination of a bifunctional alkylating agent and DNA repair inhibitors